Drug Sponsors

Pelican Products acquires Cool Logistics

Friday, February 7, 2014 02:09 PM

Behrman Capital, a private equity investment firm based in New York and San Francisco, announced that its portfolio company Pelican Products, a design and manufacturer of high-performance protective case solutions and advanced portable lighting systems, has acquired U.K.-based Cool Logistics, a provider of temperature controlled packaging solutions. Financial terms of the transaction have not been disclosed.

More... »

Myriad Genetics to acquire Crescendo Bioscience

Thursday, February 6, 2014 12:38 PM

Myriad Genetics, a molecular diagnostic company, has entered into a definitive agreement to acquire Crescendo Bioscience, a global provider of autoimmune diagnostics, for $270 million in cash which will be reduced by $25 million for the repayment of a loan made to Crescendo and customary adjustments in accordance with the acquisition agreement.

More... »


Report: Pharmaceutical firms are humanizing their brands

Thursday, February 6, 2014 11:45 AM

By 2018, it is estimated the global pharmaceutical market will be worth more than $1.3 trillion. To corner their share of profits, established drug companies have to fight fierce competition from generic products, adhere to stringent government regulations and sway a consumer base that is better informed than ever before.

More... »

Bristol-Myers Squibb completes sale of global diabetes business to AstraZeneca

Monday, February 3, 2014 08:51 AM

Bristol-Myers Squibb has completed the previously announced sale of its global diabetes business to AstraZeneca.

More... »

Wilex to implement cost-cutting, reduce workforce 80%

Friday, January 31, 2014 12:54 PM

Wilex, a biopharmaceutical company based in Munich, Germany, will implement extensive cost-cutting measures and focus on contract research and the ADC technology at its subsidiary Heidelberg Pharma. This decision was taken with the approval of the company's supervisory board.

More... »

Astrazeneca to close India R&D site

Friday, January 31, 2014 12:49 PM

AstraZeneca plans to close its Avishkar R&D site in Bangalore later this year, part of the company's broader global business strategy to simplify its R&D footprint and focus resources on three core therapy areas: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity.

More... »

Janssen R&D launches novel trial data sharing agreement with Yale School of Medicine

Thursday, January 30, 2014 10:49 AM

Johnson & Johnson subsidiary Janssen Research and Development has entered into a novel agreement with Yale School of Medicine's Open Data Access (YODA) Project to extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine. 

More... »

Medigene acquires Trianta Immunotherapies

Wednesday, January 29, 2014 01:16 PM

Medigene, a biotechnology company headquartered in Martinsried, Germany, has acquired Munich-based Trianta Immunotherapies, recently spun out from the Munich Helmholtz Center.

More... »

Midwest healthcare companies raise $758 million in 2013

Wednesday, January 29, 2014 12:55 PM

Midwest healthcare companies attracted $758 million in new investments across 217 companies in 2013, according to the BioEnterprise Midwest Healthcare Venture Investment Report. As with the nationwide trend, Midwest investment decreased from 2012. Ohio ($296 million) and Minnesota ($228 million) led Midwestern states in attracting investment dollars.

More... »

Sony, M3, Illumina to launch new genome company in Japan

Monday, January 27, 2014 01:24 PM

Sony, M3 and Illumina have formed a collaboration to launch a "genome information platform" in Japan. Sony and M3 will establish a new company, with Illumina as a minority investor, by the end of February.

More... »

Link to survey



Browse by:


December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs